Format

Send to

Choose Destination
Drug Discov Today. 2012 Mar;17(5-6):194-202. doi: 10.1016/j.drudis.2011.12.009. Epub 2011 Dec 15.

Targeting the S and G2 checkpoint to treat cancer.

Author information

1
Newcastle University, Northern Institute for Cancer Research, Newcastle-upon-Tyne, UK.

Abstract

Cell survival following DNA damage depends on activating checkpoints to arrest proliferation. Most cancer cells have dysregulated G1 checkpoints making them dependent on their S and G2 checkpoints, which are activated by ATR/Chk1 signalling. Thus, inhibiting ATR or Chk1 should selectively sensitise cancer cells to DNA damage. Genetic inactivation of ATR and Chk1 abrogates cell cycle arrest and enhances cytotoxicity following exposure to DNA-damaging agents. Similar effects were seen with small-molecule Chk1 inhibitors in preclinical studies, and clinical trial data are starting to emerge. Recently, potent ATR inhibitors have been identified that also sensitise cancer cells in vitro. ATR and Chk1 inhibitors might also cause 'synthetic lethality' in tumour cells defective in defined DNA repair pathways.

PMID:
22192883
DOI:
10.1016/j.drudis.2011.12.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center